Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01UTL
|
|||
| Former ID |
DAP001151
|
|||
| Drug Name |
Desipramine
|
|||
| Synonyms |
Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] | Approved | [1], [2], [3] | |
| Depression [ICD-11: 6A70-6A7Z] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antidepressants
|
|||
| Company |
Sanofi Aventis Us Llc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2
|
|||
| Canonical SMILES |
CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
|
|||
| InChI |
1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
|
|||
| InChIKey |
HCYAFALTSJYZDH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 50-47-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9158, 647048, 3249345, 3727070, 5321893, 7737258, 7979043, 8151907, 10524411, 11111066, 11111067, 11335365, 11360604, 11363335, 11365897, 11368459, 11371457, 11374067, 11376621, 11461576, 11466371, 11467491, 11483778, 11486062, 11487907, 11490195, 11492129, 11494255, 14774838, 29214812, 29222144, 46504624, 47291013, 47291014, 47736341, 47736342, 47736343, 47959596, 48259094, 48259095, 48415856, 49698852, 49961473, 50100220, 50104283, 53787179, 57321547, 76076257, 85209781, 85753308
|
|||
| ChEBI ID |
CHEBI:47781
|
|||
| ADReCS Drug ID | BADD_D00612 ; BADD_D00613 | |||
| SuperDrug ATC ID |
N06AA01
|
|||
| SuperDrug CAS ID |
cas=000050475
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [4] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2399). | |||
| REF 2 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.